Join Growin Stock Community!

中化生1762.TW Overview

TW StockBiotech. & Medical
(No presentation for 1762)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

中化生（1762）Overall Performance

中化生（1762）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

中化生（1762） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

中化生（1762）Key Information

中化生（1762）Profile

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and wholesale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, cardiovascular, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxants, hypolipaemics, antineoplastic, antihyperlipedemias, and immunosuppressant products, as well as provides research and development, and contract manufacturing services to new drug developers and generic drug companies. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is headquartered in New Taipei City, Taiwan.

中化生（1762）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.34
PE Ratio (TTM)
-
Forward PE
10.32
PS Ratio (TTM)
2.14
PB Ratio
0.65
Price-to-FCF
10.22
METRIC
VALUE
vs. INDUSTRY
Gross Margin
15.54%
Net Margin
-10.53%
Revenue Growth (YoY)
-29.88%
Profit Growth (YoY)
-66.78%
3-Year Revenue Growth
-35.64%
3-Year Profit Growth
-51.90%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.34
PE Ratio (TTM)
-
Forward PE
10.32
PS Ratio (TTM)
2.14
PB Ratio
0.65
Price-to-FCF
10.22
Gross Margin
15.54%
Net Margin
-10.53%
Revenue Growth (YoY)
-29.88%
Profit Growth (YoY)
-66.78%
3-Year Revenue Growth
-35.64%
3-Year Profit Growth
-51.90%
default symbol

1762

中化生

27.25D

0.55%

(0.01)

  • When is 1762's latest earnings report released?

    The most recent financial report for 中化生 (1762) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1762's short-term business performance and financial health. For the latest updates on 1762's earnings releases, visit this page regularly.

  • What is the operating profit of 1762?

    According to the latest financial report, 中化生 (1762) reported an Operating Profit of -88.42M with an Operating Margin of -57.24% this period, representing a decline of 1,758.41% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 1762's revenue growth?

    In the latest financial report, 中化生 (1762) announced revenue of 154.47M, with a Year-Over-Year growth rate of -55.64%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 1762 have?

    At the end of the period, 中化生 (1762) held Total Cash and Cash Equivalents of 253.19M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 1762 go with three margins increasing?

    In the latest report, 中化生 (1762) did not achieve the “three margins increasing” benchmark, with a gross margin of -5.97%%, operating margin of -57.24%%, and net margin of -27.56%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1762's profit trajectory and future growth potential.

  • Is 1762's EPS continuing to grow?

    According to the past four quarterly reports, 中化生 (1762)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.77. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 1762?

    中化生 (1762)'s Free Cash Flow (FCF) for the period is 10.81M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 316.31% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.